Bovine Intestinal Alkaline Phosphatase (bIAP) Modulating Rheumatoid Arthritis (ALS-003-2008)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2011 by Alloksys Life Sciences B.V..
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Aix Scientifics
Information provided by:
Alloksys Life Sciences B.V.
ClinicalTrials.gov Identifier:
NCT01416493
First received: August 11, 2011
Last updated: August 12, 2011
Last verified: August 2011
  Purpose

This is a proof of concept study asking if alkaline phosphatase injections can reduce acute inflammation in rheumatoid arthritis patients.


Condition Intervention Phase
Acute Rheumatoid Arthritis
Drug: s.c. injections of bovine intestinal Alkaline Phosphatase
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An OPEN LABEL Phase II Safety Study of Bovine Intestinal Alkaline Phosphatase (bIAP), an Inflammation Modulating Moiety, in RA Patients

Resource links provided by NLM:


Further study details as provided by Alloksys Life Sciences B.V.:

Primary Outcome Measures:
  • blood level of the pro-inflammatory cytokines: TNFα and IL6 [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
    The anticipated effects of bIAP will be short lived, within 4 days. However, in order to capture durable clinical responses or any late adverse effects, patients will be followed through 3 months at weeks 2, 4, 8 and 12 incorporating trial observations with routine monthly care to reduce disruption to patients.


Secondary Outcome Measures:
  • RA clinical status expressed as Daily Activity Score (DAS-28) [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
    van der Heijde DM, van 't Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA, van Rijswijk MH, van de Putte LB. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis. 1990 Nov;49(11):916-920


Estimated Enrollment: 10
Study Start Date: May 2011
Estimated Study Completion Date: May 2012
Estimated Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: bIAP treatment Drug: s.c. injections of bovine intestinal Alkaline Phosphatase
daily subcutaneous treatment with two injections of 2000IU bIAP for three days

Detailed Description:

This is a proof of concept study to establish the safety of subcutaneous (sc) treatment and the efficacy of alkaline phosphatase (AP) in reducing specific pro-inflammatory cytokines during and after 3 days of twice daily s.c. treatment. A total dose of 12000 Units AP will be administered by 2000 IU s.c. injection twice daily for 3 days. Subjects will be closely followed for 8 days and regular clinical observations will be made during 3 months. Close out will be 3 months after initiation of treatment.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

1. Male or non-pregnant, non-lactating female patients of any race with an age >18 years. Woman of child-bearing potential must be on regular contraceptives throughout the trial (Pregnancy tests).

1A: RA according to the 1987 revised ARA criteria (Arnett 1987) with an active disease with DAS28>3.2 despite the prior or concurrent use of DMARDs.

2. Patients may be on no active therapy or may be on continuous DMARD therapy including Methotrexate, Sulphasalazine, Leflunomide, Hydroxychloroquine, Myocrisin alone or in combination, or on NSAID treatment, or on steroid (prednisolone not more than 10mg/day).

3. Patients must have a measurable acute phase response: CRP (> 10mg/dl), ESR > 25. (to be measured on routine lab range CRP/ ESR/AP/ standard biochemistry)

4. Patients eligible for treatment with biological TNFα blockers and who are awaiting the administration of such treatment may enroll in the laboratory and safety protocols Data for Clinical Phase observations will be collected but will be handled as last observation carried forward for the final records prior to the administration of TNF blocking agent, should that occur within the 3-month Clinical Phase. The administration of TNFα blockers will not be delayed for the protocol.

5. Patients who have given written informed consent prior to participation in the trial and who undertake to comply with the protocol.

Exclusion Criteria:

  1. Patients who are unwilling or unable to be fully evaluated for follow-up.
  2. Patients who have an active infection or who are suspected of having systemic infection and or patients that are treated with antibiotics.
  3. Patients whose screening blood do not reflect a sufficient cytokine or acute phase response.
  4. Patients who have evidence of significant hepatic disease, including history of clinical signs or laboratory values of total bilirubin > 34.2 umol/L (> 2.0 mg/dL), ALT (>120) or AST (>135) corresponding to > 3X upper limit of normal.
  5. Alkaline phosphatase levels must be less 145 IU/L (routine clinical method)
  6. Patients who received investigational drugs in the 30 days prior to study drug administration, or are currently participating in a study during which the administration of investigational drugs within one month is anticipated.
  7. Patients who have renal insufficiency (history of creatinine >177umol/L or >2.0 mg/dL) or chronic renal failure requiring dialysis.
  8. Patients with severe neurological deficits (see Appendix I).
  9. Patients who have a recent history of drug substance or alcohol abuse.
  10. Patients with a diagnosis of idiopathic thrombocytopenia.
  11. Patients with a history of cancer who have received chemotherapy or radiation therapy within the past 3 months. Patients receiving only adjuvant hormonal therapy are not excluded. If the cancer has not resolved completely, the patient should not be enrolled without permission of Alloksys.
  12. Patients receiving oral glucocorticoids >10mg /day or any IV, IM or Intra articular dosing within 30 days of commencing the protocol.
  13. Patients who are vegetarians or veganists or those patients that may be expected not to be tolerant to bovine proteins, or not to wish exposure to bovine proteins for personal reasons.
  14. Patients who are, in the opinion of the Investigator or the Sponsor, unsuitable for the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01416493

Contacts
Contact: Anthony Hammond, MD +44 1622 224876 tony_hammond@online.rednet.co.uk

Locations
United Kingdom
Maidstone Hospital, Dept. Rheumatology Recruiting
Maidstone, Kent, United Kingdom, ME16 9QQ
Contact: Anthony Hammond, MD    +44 1622 224876    tony_hammond@online.rednet.co.uk   
Principal Investigator: Anthony Hammond, MD         
Sponsors and Collaborators
Alloksys Life Sciences B.V.
Aix Scientifics
Investigators
Principal Investigator: Anthony Hammond, MD Maidstone Hospital, Dept. Rheumatology
  More Information

Additional Information:
No publications provided

Responsible Party: Dr. Ruud Brands, Alloksys Life Sciences B.V.
ClinicalTrials.gov Identifier: NCT01416493     History of Changes
Other Study ID Numbers: REUMAP, 2008-007346-63
Study First Received: August 11, 2011
Last Updated: August 12, 2011
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by Alloksys Life Sciences B.V.:
acute rheumatoid arthritis

Additional relevant MeSH terms:
Arthritis
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases

ClinicalTrials.gov processed this record on July 23, 2014